STOCK2S-26016 is a WNK signalling inhibitors. STOCK2S-26016 inhibits WNK4 and WNK1 with IC 50 s of 16 μM and 34.4 μM, respectively. STOCK2S-26016 has potential for antihypertensive research.
性状
Solid
IC50 & Target[1][2]
IC50: 16 μM (WNK4); 34.4 μM (WNK1)
体外研究(In Vitro)
STOCK2S-26016 (10 and 30 minutes) blocks the effect of L-NAME on phosphorylated sodium-chloride cotransporter (NCC) in mDCT cells.STOCK2S-26016 (25-200 μM) drastically and dose-dependently reduces the phosphorylation of STE20/SPS1-related proline/alanine-rich protein kinase (SPAK) and NCC in mpkDCT cells.STOCK2S-26016 (50-200 μM) drastically and dose-dependently reduces the phosphorylation of SPAK and Na/K/Cl cotransporter 1 (NKCC1) in MOVAS cells. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;In solvent -80°C 6 months
参考文献
[1]. Takayasu M, et, al. Chemical library screening for WNK signalling inhibitors using fluorescence correlation spectroscopy. Biochem J. 2013 Nov 1; 455(3): 339-45.[2]. Conghui W, et, al. Low dose L-NAME induces salt sensitivity associated with sustained increased blood volume and sodium-chloride cotransporter activity in rodents. Kidney Int. 2020 Jun 24; S0085-2538(20)30703-1.